Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
27 Marzo 2020 - 7:00AM
Sanofi and Translate Bio collaborate to develop novel mRNA vaccine
candidate against COVID-19
Sanofi and Translate Bio collaborate to develop novel
mRNA vaccine candidate against COVID-19
*The two companies will jointly investigate multiple candidates
with the goal of advancing an efficacious and safe SARS-CoV-2
vaccine into clinical development
PARIS and LEXINGTON, MASS. - March 27,
2020 – Sanofi Pasteur, the vaccines global business unit
of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage
messenger RNA (mRNA) therapeutics company, will collaborate to
develop a novel mRNA vaccine for COVID-19. This collaboration
leverages an existing agreement from 2018 between the two companies
to develop mRNA vaccines for infectious diseases.
Translate Bio has begun to produce multiple mRNA
constructs and will use its mRNA platform to discover, design, and
manufacture a number of SARS-CoV-2 vaccine candidates. Sanofi will
provide deep vaccine expertise and support from its external
research networks to advance vaccine candidates for potential
further development. Translate Bio has established 100 gram
single-batch production with its clinical-stage mRNA therapeutics
platform. Build-out is underway of dedicated manufacturing space
through a contract manufacturing partner to accommodate at least
two 250-gram batches per month. Depending on the final human
dose, the mRNA platform of Translate Bio has excellent promise to
meet the future demands for a pandemic response.
For Sanofi, this marks a second collaboration in
its efforts to develop a novel COVID-19 vaccine candidate. In
February 2020, Sanofi announced a collaboration with the Biomedical
Advanced Research and Development Authority (BARDA) to advance a
novel COVID-19 vaccine candidate. The agreement with BARDA calls
for Sanofi to initiate development of a recombinant, protein-based
vaccine candidate against COVID-19.
“We are committed to leveraging different ways
to address the COVID-19 public health crisis by testing treatments,
as well as two vaccines using different platforms. We believe the
more approaches we explore, the better our likelihood of success in
achieving this goal,” said David Loew, Global Head of Vaccines at
Sanofi. “Having sufficient installed capacity will be key to
satisfy the strong demand for vaccines we will probably see, and
based on the experience we’ve had under the collaboration to date,
we believe the Translate Bio mRNA platform could help us meet that
need.”
“The Translate Bio and Sanofi Pasteur teams have
generated encouraging preclinical data across multiple infectious
disease targets, as part of our ongoing mRNA vaccine collaboration.
This work will serve as a strong foundation as we direct joint
research efforts against COVID-19 to help address this public
health threat,” said Ronald Renaud, Chief Executive Officer of
Translate Bio. “Our collaborative efforts to combat COVID-19 will
leverage Translate Bio’s innovative mRNA platform as well as
Sanofi’s vaccine expertise and ongoing COVID-19 research with the
goal of advancing a novel mRNA vaccine rapidly to the clinic.”
About mRNA Vaccines
Vaccines work by mimicking disease agents to stimulate the immune
system; building up a defense mechanism that remains active in the
body to fight future infections. mRNA vaccines offer an innovative
approach by delivering a nucleotide sequence encoding the antigen
or antigens selected for their high potential to induce a
protective immune response. mRNA vaccines also represent a
potentially innovative alternative to conventional vaccine
approaches for several reasons - their high potency, ability to
initiate protein production without the need for nuclear entry,
capacity for rapid development and potential for low-cost
manufacture and safe administration using non-viral delivery. This
approach potentially enables the development of vaccines for
disease areas where vaccination is not a viable option today.
Additionally, a desired antigen or multiple antigens can be
expressed from mRNA without the need to adjust the production
process offering maximum flexibility and efficiency in
development.
About the Sanofi Pasteur/Translate Bio
CollaborationIn 2018, Translate Bio entered into a
collaboration and exclusive licensing agreement with Sanofi Pasteur
Inc., the vaccines global business unit of Sanofi, to develop mRNA
vaccines for up to five infectious disease pathogens. This
collaboration brings together Sanofi Pasteur’s leadership in
vaccines and Translate Bio’s mRNA research and development
expertise. Under the agreement, the companies are jointly
conducting research and development activities to advance mRNA
vaccines and mRNA vaccine platform development during a three-year
research term. Translate Bio and Sanofi Pasteur have advanced the
preclinical development vaccine programs including screening,
optimization and production of mRNA and LNP formulations across
multiple targets.
About Translate BioTranslate
Bio is a clinical-stage mRNA therapeutics company developing a new
class of potentially transformative medicines to treat diseases
caused by protein or gene dysfunction. Translate Bio is
primarily focused on applying its technology to treat pulmonary
diseases caused by insufficient protein production or where the
reduction of proteins can modify disease. Translate Bio’s lead
program is being developed as a treatment for cystic fibrosis (CF)
and is in an ongoing Phase 1/2 clinical trial. The Company also
believes its technology is applicable to a broad range of diseases,
including diseases that affect the liver. Additionally, the
platform may be applied to various classes of treatments, such as
therapeutic antibodies or vaccines in areas such as infectious
disease and oncology. For more information about the Company,
please visit www.translate.bio or on Twitter at @TranslateBio.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contact for Sanofi Ashleigh
KossTel: +1 (908) 981-8745Ashleigh.Koss@sanofi.com Media
Relations Contact for Translate Bio Maura GavaghanTel: +1
(617) 233-1154mgavaghan@translate.bio |
Investor
Relations Contact for Sanofi Felix Lausher Tel.: +33 (0)1
53 77 45 45 ir@sanofi.com Investor Relations Contact
for Translate BioTeri Dahlman Tel: +1 (617)
817-8655tdahlman@translate.bio |
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, the impact of
global disruptions, including pandemics, cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2019. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Translate Bio Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
those regarding: Translate Bio’s expectations with respect to
its collaboration with Sanofi; Translate Bio’s beliefs regarding
the broad applicability of its MRT platform; and Translate Bio’s
plans, strategies and prospects for its business, including its
lead development programs. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “forward,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from
current expectations and beliefs, including but not limited to:
Translate Bio’s ability to advance the development of its platform
and programs under the timelines it projects, demonstrate the
requisite safety and efficacy of its product candidates and
replicate in clinical trials any positive findings from preclinical
studies; the content and timing of decisions made by the FDA, other
regulatory authorities and investigational review boards at
clinical trial sites, including decisions as it relates to ongoing
and planned clinical trials; Translate Bio’s ability to obtain,
maintain and enforce necessary patent and other intellectual
property protection; the availability of significant cash required
to fund operations; competitive factors; general economic and
market conditions and other important risk factors set forth under
the caption “Risk Factors” in Translate Bio’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2019 filed with
the Securities and Exchange Commission on March 12, 2020 and in any
other subsequent filings made by Translate Bio. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Translate Bio specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise. |
Grafico Azioni Sanofi (BIT:1SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (BIT:1SAN)
Storico
Da Apr 2023 a Apr 2024